---
title: "SINOTHERAPEUTICS: Dapagliflozin Metformin Extended-Release Tablets have received approval from the U.S. FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239782700.md"
description: "SINOTHERAPEUTICS announced that its Dapagliflozin Metformin Extended-Release Tablets have received temporary approval from the U.S. FDA. This approval indicates that the product meets the review requirements for generic drugs, but due to patent protection, it cannot be sold in the U.S. market until the patent expires and final approval is obtained. This move will help the company expand its sales scale in the U.S. market, enrich its product line, and have a positive impact on long-term operations"
datetime: "2025-05-12T07:50:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239782700.md)
  - [en](https://longbridge.com/en/news/239782700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239782700.md)
generator: "portal-rs"
---

# SINOTHERAPEUTICS: Dapagliflozin Metformin Extended-Release Tablets have received approval from the U.S. FDA

According to the Zhitong Finance APP, SINOTHERAPEUTICS (688247.SH) announced that it recently received notification from the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA") that the abbreviated new drug application (hereinafter referred to as "ANDA", i.e., U.S. generic drug application) for Dapagliflozin Metformin Extended-Release Tablets submitted to the U.S. FDA has received Tentative Approval.

The Tentative Approval of Dapagliflozin Metformin Extended-Release Tablets by the U.S. FDA indicates that the product meets all review requirements for generic drugs. However, the product is still under patent protection in the U.S., and the company must wait for the relevant patent to expire and obtain final approval from the U.S. FDA before it can qualify to sell the product in the U.S. market. The Tentative Approval of Dapagliflozin Metformin Extended-Release Tablets by the FDA will help the company continuously expand its sales scale in the U.S. market, enrich its product lineup, and have a positive impact on the company's long-term operations

### Related Stocks

- [688247.CN](https://longbridge.com/en/quote/688247.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Oura exploring how its ring could detect brain hemorrhages after Bill Ackman suggests it could have helped his daughter](https://longbridge.com/en/news/296658401.md)
- [APT Medical: H1 2026 revenue and profit rose over 25% year-over-year, with strong growth in core segments](https://longbridge.com/en/news/296363764.md)
- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)
- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**